Navigation Links
Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management
Date:11/9/2010

esponse and was well tolerated. Vaccine-related serious side-effects which would raise any safety concern were not observed. The results provide a strong basis for evaluation of further development options. Intercell and its partner Novartis will determine next steps.

Clostridium difficile program planned to enter clinic: After successful pre-clinical trials, Intercell is progressing its vaccine candidate to prevent infections with Clostridium difficile (C. diff). C. diff is the leading cause for nosocomial Diarrhea in Europe and the U.S. A Phase I clinical study is expected to start in 2010.

Staphylococcus aureus vaccine (V710) on track: The Phase II/III study conducted and funded by Merck & Co., Inc. in cardiothoracic surgery patients for the investigational S. aureus vaccine is progressing to plan. The first critical interim analysis (surpassing futility) is expected in 2011.

Good progress in development pipeline – programs progressing according to plan

  • Recruitment for the pivotal Phase III study of approximately 2,000 travelers for Intercell's investigational Travelers' Diarrhea (TD) Vaccine Patch is completed. The first data from that trial, conducted in travelers to Mexico and Guatemala, is expected for end 2010/early 2011. The enrollment of a complementary 800-traveler Phase II study in those travelling to India has also been completed; first data is expected in Q4 2010. The trial in India is the first study outside South America and has the potential to demonstrate proof of concept for the vaccine in Asia.
  • Intercell will pursue activities with GSK to prepare markets as soon as data on Phase II and Phase III trials becomes available. Diarrhea is the most common health problem among travelers from developed countries who visit developing areas and most of the diarrheal cases in travelers are caused by bacteria, primarily by ETEC strains (Escherichia coli).
  • Intercell and GSK will continue de
    '/>"/>

  • SOURCE Intercell AG
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
    2. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
    3. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
    4. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
    5. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
    6. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
    7. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
    8. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
    9. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
    10. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
    11. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... 2014 /PRNewswire-iReach/ -- CaPtivate Pharmaceuticals LLC, a ... phosphate (CaP)-based nanoparticle drug and vaccine delivery technologies, ... License Agreement with Immunotope Inc., another ... for the treatment and prevention of viral infections ... of the agreement, Immunotope is granted a non-exclusive ...
    (Date:9/15/2014)... , Sept. 15, 2014 PDL BioPharma, Inc. (PDL) ... has paid the September 12, 2014, regular quarterly dividend payment ... of PDL as of September 5, 2014, the record date. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
    (Date:9/15/2014)... DUBLIN , Sept. 15, 2014 ... "Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014" ... (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 presents comprehensive ... Europe , Asia , ... The report includes paracetamol (acetaminophen) description, covers its ...
    Breaking Medicine Technology:CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3
    (Date:9/16/2014)... 16, 2014 DiaperBuys, a national online ... Aging’ Month this September. Healthy Aging Month was started ... the nation on the positive aspects of growing older. ... conditions or side effects from medications that cause urinary ... Manager for DiaperBuys.com. “This can seem daunting to some ...
    (Date:9/16/2014)... 16, 2014 Banish headaches forever with ... approved Cefaly device for chronic migraine relief and treatment. ... the United States. Until now, US patients would directly ... in Belgium and wait 2-3 weeks for their device ... United States and once prescription and payment is received, ...
    (Date:9/16/2014)... Reading, MA (PRWEB) September 16, 2014 ... announce its partnership with Fairfax Egg Bank. The collaboration ... and expand the donor egg offering at the Fertility ... operated since 2006 and offers the nation’s largest selection ... is advantageous for several reasons:, , ...
    (Date:9/15/2014)... (PRWEB) September 16, 2014 The team ... Carey Danis & Lowe report that the ... was found responsible for the injuries that a woman ... to treat stress urinary incontinence (SUI). , Carey Danis ... medical device litigation and personal injury law. The St. ...
    (Date:9/15/2014)... 2014 Hastings and Hastings, an experienced ... announces one flat attorney fee for personal injury cases. ... the largest portion possible of their settlement or recovery ... and damaged personal property. In addition, Hastings and Hastings ... simply states that no fees are due unless a ...
    Breaking Medicine News(10 mins):Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 3Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3
    ... , SAN BERNARDINO, Calif., Aug. 11 ... its customers and employees recently raised $266,429.00 to benefit the Leukemia ... has raised over $460,000 for this organization. , , ... the month of June 2009, Stater Bros., customers and employees at ...
    ... , WASHINGTON, Aug. 11 Even while ... is showing hospitals owned and operated by physicians among the best in the ... of "healthcare reform." , , The independent testing and research ... patients around the country. Overwhelmingly, Cons u mer ...
    ... Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) ... the U.S. Food and Drug Administration,s (FDA) complete response ... trazodone. , As previously announced, Labopharm received a complete ... indicating the Company,s new drug application (NDA) for its ...
    ... public survey conducted in Europe found that the vast ... and prostate cancer screening, according to a new study ... the National Cancer Institute . Gerd Gigerenzer, of ... and colleagues conducted a survey of over 10,200 people ...
    ... , , , , ... SCOR ), a leader in measuring the digital world, today ... the effects of increasing U.S. unemployment on online consumer activity. While ... substantial declines, there has been a corresponding increase in the number ...
    ... Healthcare reform has become a hot button issue for politicians and ... clear the air and separate fact from fiction. , , ... e QtY97yVQFUg6so , , ... and unrestricted use at http://www.medi a ...
    Cached Medicine News:Health News:Stater Bros. Raises $266,429.00 for the Leukemia & Lymphoma Society 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 3Health News:Labopharm submits response to FDA for novel antidepressant 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3
    ... The R4Mplus offers global companies ... help meet RFID compliance initiatives. With ... a variety of connectivity options, and ... is a super value. Plus, the ...
    ... The 105SL combines enhanced memory, ... rugged and reliable all-metal construction. ... processing and print speed make ... users who value reliability, productivity, ...
    ... R4Mplus offers global companies a cost-effective ... RFID compliance initiatives. With die-cast metal ... of connectivity options, and complex multi-language ... super value. Plus, the fully integrated ...
    ... Ideal for patient wristband printing, the ... reliable and accurate scanning for improved patient ... text, and graphics on a variety of ... printer prints patient ID wristbands on demand. ...
    Medicine Products: